| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Chemical and Biochemical Engineering, Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey 08854-8058
Correspondence: Address reprint requests to Charles M. Roth, Dept. of Chemical and Biochemical Engineering, Dept. of Biomedical Engineering, Rutgers University, 98 Brett Rd., Rm. C-228, Piscataway, NJ 08854-8058. Tel.: 732-445-4109; Fax: 732-445-2581; E-mail: cmroth{at}rci.rutgers.edu.
Antisense oligonucleotides present a powerful means to inhibit expression of specific genes, but their effectiveness is limited by factors including cellular delivery, biochemical attack, and poor binding to target. We have developed a systems model of the processes required for an antisense oligonucleotide to enter, gain access to its target mRNA, and exert activity in a cell. The model accurately mimics observed trends in antisense effectiveness with the stability of the oligonucleotide backbone and with the affinity/kinetics of binding to the mRNA over the time course of inhibition. By varying the model parameters within the physically realizable range, we note that the major molecular and cellular barriers to antisense effectiveness are intracellular trafficking, oligonucleotide-mRNA binding rate, and nuclease degradation of oligonucleotides, with a weaker dependence on total cellular uptake than might be expected. Furthermore, the model may serve as a predictive tool to design and test strategies for the cellular use of antisense oligonucleotides. The use of integrated mathematical modeling can play a significant role in the development of antisense and related technologies.
This article has been cited by other articles:
![]() |
D. W. Bartlett and M. E. Davis Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging Nucleic Acids Res., January 12, 2006; 34(1): 322 - 333. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |